NASDAQ: SPTX
Seaport Therapeutics, Inc.CIK 0002042347 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Seaport Therapeutics debuts with $238.7M IPO, advancing two neuropsychiatric trials
5 material changes detected. Sign up free to read the summary.
Seaport Therapeutics reports Q1 2026 financial results
2 material changes detected. Sign up free to read the summary.
Partner
Trade SPTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Seaport Therapeutics completes IPO, Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) with 700M shares
4 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Jun 8, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 21.4 | 10.5 |
| General and administrative | 6.1 | 5.7 |
| Total operating expenses | 27.5 | 16.2 |
| Operating income | (27.5) | (16.2) |
| Other income/(expense), net | 2.7 | 3.1 |
| Income before income taxes | (24.9) | (13.1) |
| Income tax expense/(benefit) | 0.5 | 0.03 |
| Net income | (25.4) | (13.1) |
| Basic earnings per share | (10.34) | (5.65) |
| Diluted earnings per share | (10.34) | (5.65) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 52.9 | 46.0 |
| Short-term investments | 129.7 | 169.9 |
| Prepaid expenses and other current assets | 5.7 | 7.2 |
| Total current assets | 188.3 | 223.2 |
| Property, plant and equipment, net | 0.4 | 0.4 |
| Operating lease right-of-use assets, net | 5.1 | 4.8 |
| Deferred income taxes and other assets | 3.8 | 2.9 |
| Other long-term assets | 30.0 | 17.7 |
| TOTAL ASSETS | 227.7 | 249.0 |
| Current liabilities: | ||
| Accounts payable | 4.8 | 2.0 |
| Current portion of operating lease liabilities | 1.6 | 1.6 |
| Accrued liabilities | 0.01 | 0.01 |
| Other current liabilities | 7.8 | 9.1 |
| Total current liabilities | 14.2 | 12.8 |
| Operating lease liabilities | 3.7 | 3.4 |
| Total liabilities | 18.0 | 16.2 |
| Redeemable preferred stock | 325.3 | 325.3 |
| Shareholders' equity: | ||
| Common stock | — | — |
| Capital in excess of stated value | 23.8 | 21.3 |
| Accumulated other comprehensive income (loss) | 0.06 | 0.3 |
| Retained earnings (deficit) | (139.5) | (114.1) |
| Total shareholders' equity | (115.6) | (92.5) |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 227.7 | 249.0 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (20.2) | (20.2) |
| Investing Activities: | ||
| Net cash from investing activities | 27.9 | (225.6) |
| Financing Activities: | ||
| Net cash from financing activities | (0.8) | — |
| Net increase/(decrease) in cash | 6.9 | (245.8) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗